MRO-002 / Myrobalan Therap - LARVOL DELTA

Myrobalan Therapeutics Awarded a Grant from the National Multiple Sclerosis Society to Advance Development of MRO-002 in Multiple Sclerosis (Businesswire) - "Myrobalan Therapeutics...today announced a grant of over $850,000 from the National Multiple Sclerosis Society to support the preclinical and translational development of MRO-002, a G-protein-coupled receptor 17 (GPR17) antagonist, for the treatment of progressive multiple sclerosis (MS)."

Financing • Immunology • Multiple Sclerosis

Myrobalan to present GPR17 antagonist preclinical data at ECTRIMS 2024 (Businesswire) - "Myrobalan Therapeutics...announced data demonstrating that their small molecule G protein-coupled receptor 17 (GPR17) antagonists show a biological effect in a number of in vitro and in vivo preclinical models. The data were presented in a poster at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), taking place in Copenhagen, Denmark, September 17–20, 2024. The ECTRIMS data demonstrate an effect by Myrobalan’s GPR17 antagonists on oligodendrocyte maturation, a requirement for remyelination, compared to controls in human induced pluripotent stem cell-derived oligodendrocytes and in multiple mouse models of demyelination. Enhanced remyelination was also observed after treatment with a GPR17-antagonist compound in a mouse model."

Preclinical • CNS Disorders • Multiple Sclerosis